UNIVEST FINANCIAL Corp Lowers Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• UNIVEST FINANCIAL Corp reduced its holdings in Intuitive Surgical by 12.8%, now owning 8,209 shares valued at approximately $4.07 million.
• Multiple hedge funds have increased their stakes in Intuitive Surgical, with institutional investors owning 83.64% of the company's stock.
• Analysts have raised their price targets for Intuitive Surgical, with an average target of $592.05 and ratings ranging from "sell" to "buy" indicating overall positive sentiment.

UNIVEST FINANCIAL Corp decreased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 12.8% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,209 shares of the medical equipment provider's stock after selling 1,206 shares during the period. UNIVEST FINANCIAL Corp's holdings in Intuitive Surgical were worth $4,066,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ISRG. Chilton Capital Management LLC increased its holdings in shares of Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the period. Parvin Asset Management LLC bought a new position in shares of Intuitive Surgical during the fourth quarter worth approximately $26,000. Global Financial Private Client LLC lifted its holdings in shares of Intuitive Surgical by 253.3% during the 1st quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 38 shares during the period. Elite Financial Inc. bought a new stake in shares of Intuitive Surgical during the 1st quarter worth approximately $26,000. Finally, Hurley Capital LLC bought a new stake in shares of Intuitive Surgical during the 4th quarter worth approximately $28,000. Institutional investors own 83.64% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wells Fargo & Company upped their price target on shares of Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft downgraded shares of Intuitive Surgical from a "hold" rating to a "sell" rating and cut their price target for the stock from $515.00 to $440.00 in a report on Monday, June 9th. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. UBS Group lifted their price target on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Finally, Evercore ISI lifted their price target on shares of Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $595.95.

Intuitive Surgical Stock Down 1.2%

ISRG traded down $5.95 during trading on Tuesday, hitting $477.41. The company's stock had a trading volume of 1,952,511 shares, compared to its average volume of 2,007,824. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00. The stock's fifty day moving average price is $522.89 and its 200-day moving average price is $531.90. The firm has a market capitalization of $171.14 billion, a P/E ratio of 66.57, a PEG ratio of 5.06 and a beta of 1.59.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The firm had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business's revenue was up 21.4% on a year-over-year basis. During the same period last year, the company earned $1.78 earnings per share. Equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insider Transactions at Intuitive Surgical

In other news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the sale, the senior vice president owned 907 shares in the company, valued at $510,740.77. This trade represents a 19.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gary S. Guthart sold 7,893 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $498.64, for a total transaction of $3,935,765.52. Following the sale, the insider owned 13,187 shares in the company, valued at $6,575,565.68. The trade was a 37.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,903 shares of company stock worth $7,932,778 in the last 90 days. Insiders own 0.70% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.